BioNexus Gene Lab Corp.
BGLC · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $4,989 | $9,127 | $164,271 | $364,837 |
| - Cash | $4,377 | $5,929 | $2,119 | $2,124 |
| + Debt | $211 | $147 | $57 | $77 |
| Enterprise Value | $822 | $3,344 | $162,209 | $362,790 |
| Revenue | $9,511 | $9,771 | $10,929 | $13,363 |
| % Growth | -2.7% | -10.6% | -18.2% | – |
| Gross Profit | $1,290 | $1,329 | $1,259 | $2,194 |
| % Margin | 13.6% | 13.6% | 11.5% | 16.4% |
| EBITDA | -$1,421 | -$2,485 | -$186 | $1,164 |
| % Margin | -14.9% | -25.4% | -1.7% | 8.7% |
| Net Income | -$1,598 | -$2,629 | -$356 | $752 |
| % Margin | -16.8% | -26.9% | -3.3% | 5.6% |
| EPS Diluted | -0.9 | -1.53 | -0.25 | 0.53 |
| % Growth | 41.2% | -512% | -147.2% | – |
| Operating Cash Flow | -$2,234 | -$1,761 | $552 | $9 |
| Capital Expenditures | -$227 | -$149 | -$54 | -$3 |
| Free Cash Flow | -$2,461 | -$1,910 | $498 | $6 |